Back to Journals » Drug Design, Development and Therapy » Volume 14 » Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
Please verify you are not a robot.